New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Core Insights - A landmark meta-analysis published in The Lancet Respiratory Medicine indicates that CPAP therapy significantly reduces mortality risks for individuals with obstructive sleep apnea (OSA), showing a 37% lower risk of all-cause death and a 55% lower risk of cardiovascular-related death [1][2][8] Company Overview - Resmed, a leader in health technology focused on sleep and breathing, announced the publication of this meta-analysis, which analyzed data from over 1 million OSA patients globally, providing strong evidence that CPAP therapy not only alleviates symptoms but also prolongs life [2][3] - The company emphasizes the importance of consistent CPAP use, as untreated OSA is a major modifiable risk factor for mortality [3][4] Industry Context - OSA affects over one billion people worldwide, with more than 80% of cases undiagnosed and untreated, leading to serious health conditions such as hypertension, diabetes, and cardiovascular disease [3][4] - The study reinforces CPAP therapy as the gold standard for OSA treatment, highlighting its effectiveness without the need for drugs or invasive procedures [3][4] Research Findings - The meta-analysis is the largest of its kind, pooling data from 30 studies, including 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years [4][5] - A dose-response relationship was identified, indicating that increased consistency in CPAP use correlates with greater survival benefits for OSA patients [8]